Medpace Soars: Earnings Beat and Bullish Outlook
Update: 2025-10-22
Description
Medpace stock skyrocketed almost 19% after crushing Q3 earnings! The clinical research firm exceeded analyst expectations with a $3.86 adjusted EPS and $660M in revenue, fueled by a 48% surge in new business awards. With a boosted full-year revenue outlook and aggressive stock buybacks, Medpace is showing no signs of slowing down.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
